Exelixis, Inc. (EXEL)
USD 39.6
(1.83%)
USD 39.6
(1.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 170.88 Million USD | -15.19% |
| 2022 | 201.48 Million USD | -29.71% |
| 2021 | 286.66 Million USD | 160.46% |
| 2020 | 110.06 Million USD | -70.21% |
| 2019 | 369.47 Million USD | -15.81% |
| 2018 | 438.85 Million USD | 164.51% |
| 2017 | 165.91 Million USD | 689.92% |
| 2016 | -28.12 Million USD | 76.84% |
| 2015 | -121.42 Million USD | 45.9% |
| 2014 | -224.45 Million USD | -11.82% |
| 2013 | -200.73 Million USD | -63.95% |
| 2012 | -122.43 Million USD | -236.75% |
| 2011 | 89.53 Million USD | 197.96% |
| 2010 | -91.39 Million USD | 25.03% |
| 2009 | -121.9 Million USD | 32.01% |
| 2008 | -179.31 Million USD | -14.18% |
| 2007 | -157.04 Million USD | -23.9% |
| 2006 | -126.75 Million USD | -34.86% |
| 2005 | -93.99 Million USD | 30.48% |
| 2004 | -135.2 Million USD | -40.46% |
| 2003 | -96.25 Million USD | -9.6% |
| 2002 | -87.82 Million USD | -16.61% |
| 2001 | -75.31 Million USD | -75.7% |
| 2000 | -42.86 Million USD | -128.0% |
| 1999 | -18.8 Million USD | -22.91% |
| 1998 | -15.29 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 136.07 Million USD | -50.76% |
| 2024 Q1 | 29.46 Million USD | -63.98% |
| 2024 Q2 | 276.34 Million USD | 837.98% |
| 2023 Q3 | -17.58 Million USD | -122.59% |
| 2023 Q4 | 81.78 Million USD | 565.15% |
| 2023 Q1 | 21.97 Million USD | 145.71% |
| 2023 Q2 | 77.85 Million USD | 254.27% |
| 2023 FY | 170.88 Million USD | -15.19% |
| 2022 Q1 | 87.05 Million USD | -25.37% |
| 2022 Q4 | -48.07 Million USD | -158.2% |
| 2022 Q3 | 82.61 Million USD | -1.31% |
| 2022 FY | 201.48 Million USD | -29.71% |
| 2022 Q2 | 83.7 Million USD | -3.84% |
| 2021 Q4 | 116.64 Million USD | 125.96% |
| 2021 FY | 286.66 Million USD | 160.46% |
| 2021 Q1 | -4.6 Million USD | -118.96% |
| 2021 Q2 | 123 Million USD | 2770.02% |
| 2021 Q3 | 51.62 Million USD | -58.03% |
| 2020 Q2 | 75.53 Million USD | 43.03% |
| 2020 FY | 110.06 Million USD | -70.21% |
| 2020 Q3 | -42.58 Million USD | -156.37% |
| 2020 Q4 | 24.29 Million USD | 157.06% |
| 2020 Q1 | 52.8 Million USD | -31.7% |
| 2019 FY | 369.47 Million USD | -15.81% |
| 2019 Q2 | 91.98 Million USD | 8.79% |
| 2019 Q1 | 84.55 Million USD | -24.23% |
| 2019 Q4 | 77.31 Million USD | -33.12% |
| 2019 Q3 | 115.6 Million USD | 25.67% |
| 2018 Q2 | 85.77 Million USD | -26.26% |
| 2018 FY | 438.85 Million USD | 164.51% |
| 2018 Q1 | 116.3 Million USD | 210.72% |
| 2018 Q3 | 125.17 Million USD | 45.94% |
| 2018 Q4 | 111.6 Million USD | -10.84% |
| 2017 Q2 | 27.11 Million USD | 34.32% |
| 2017 Q3 | 81.18 Million USD | 199.41% |
| 2017 FY | 165.91 Million USD | 689.92% |
| 2017 Q1 | 20.18 Million USD | -48.09% |
| 2017 Q4 | 37.43 Million USD | -53.89% |
| 2016 Q2 | -25.13 Million USD | 48.84% |
| 2016 FY | -28.12 Million USD | 76.84% |
| 2016 Q3 | 7.26 Million USD | 128.9% |
| 2016 Q4 | 38.88 Million USD | 435.28% |
| 2016 Q1 | -49.13 Million USD | -55.49% |
| 2015 FY | -121.42 Million USD | 45.9% |
| 2015 Q4 | -31.6 Million USD | 11.68% |
| 2015 Q3 | -35.78 Million USD | -14.39% |
| 2015 Q2 | -31.28 Million USD | -37.43% |
| 2015 Q1 | -22.76 Million USD | 50.74% |
| 2014 Q2 | -61.68 Million USD | 5.08% |
| 2014 Q3 | -51.57 Million USD | 16.4% |
| 2014 Q1 | -64.98 Million USD | -9.2% |
| 2014 Q4 | -46.2 Million USD | 10.4% |
| 2014 FY | -224.45 Million USD | -11.82% |
| 2013 Q1 | -34.01 Million USD | 18.97% |
| 2013 FY | -200.73 Million USD | -63.95% |
| 2013 Q2 | -51.29 Million USD | -50.82% |
| 2013 Q4 | -59.51 Million USD | -6.44% |
| 2013 Q3 | -55.91 Million USD | -9.0% |
| 2012 Q3 | -25.44 Million USD | 22.25% |
| 2012 Q4 | -41.97 Million USD | -64.97% |
| 2012 Q2 | -32.72 Million USD | -46.77% |
| 2012 Q1 | -22.29 Million USD | -143.23% |
| 2012 FY | -122.43 Million USD | -236.75% |
| 2011 FY | 89.53 Million USD | 197.96% |
| 2011 Q1 | -23.73 Million USD | -68.18% |
| 2011 Q2 | -18 Million USD | 24.11% |
| 2011 Q3 | 79.69 Million USD | 542.58% |
| 2011 Q4 | 51.57 Million USD | -35.29% |
| 2010 Q2 | -25.63 Million USD | 45.99% |
| 2010 Q4 | -14.11 Million USD | -235.55% |
| 2010 FY | -91.39 Million USD | 25.03% |
| 2010 Q1 | -47.45 Million USD | -56.59% |
| 2010 Q3 | -4.2 Million USD | 83.59% |
| 2009 Q1 | -36.77 Million USD | 6.43% |
| 2009 Q4 | -30.3 Million USD | -80.19% |
| 2009 Q3 | -16.81 Million USD | 55.76% |
| 2009 Q2 | -38.01 Million USD | -3.37% |
| 2009 FY | -121.9 Million USD | 32.01% |
| 2008 Q3 | -44.6 Million USD | 8.38% |
| 2008 Q2 | -48.68 Million USD | -4.21% |
| 2008 FY | -179.31 Million USD | -14.18% |
| 2008 Q1 | -46.72 Million USD | -9.26% |
| 2008 Q4 | -39.3 Million USD | 11.89% |
| 2007 Q1 | -33.35 Million USD | 1.17% |
| 2007 Q2 | -38.3 Million USD | -14.82% |
| 2007 Q3 | -42.62 Million USD | -11.29% |
| 2007 FY | -157.04 Million USD | -23.9% |
| 2007 Q4 | -42.76 Million USD | -0.32% |
| 2006 FY | -126.75 Million USD | -34.86% |
| 2006 Q1 | -31.05 Million USD | -5.29% |
| 2006 Q2 | -30.38 Million USD | 2.17% |
| 2006 Q3 | -31.56 Million USD | -3.88% |
| 2006 Q4 | -33.75 Million USD | -6.95% |
| 2005 Q3 | -27.89 Million USD | -189.28% |
| 2005 FY | -93.99 Million USD | 30.48% |
| 2005 Q2 | -9.64 Million USD | 64.24% |
| 2005 Q1 | -26.96 Million USD | 47.23% |
| 2005 Q4 | -29.49 Million USD | -5.75% |
| 2004 Q4 | -51.09 Million USD | -91.81% |
| 2004 FY | -135.2 Million USD | -40.46% |
| 2004 Q1 | -28.61 Million USD | -21.7% |
| 2004 Q3 | -26.63 Million USD | 7.7% |
| 2004 Q2 | -28.85 Million USD | -0.87% |
| 2003 Q1 | -23.3 Million USD | -11.29% |
| 2003 Q2 | -24.31 Million USD | -4.33% |
| 2003 Q3 | -25.12 Million USD | -3.33% |
| 2003 FY | -96.25 Million USD | -9.6% |
| 2003 Q4 | -23.51 Million USD | 6.43% |
| 2002 Q3 | -22.97 Million USD | 0.39% |
| 2002 Q1 | -19.9 Million USD | -6.17% |
| 2002 Q2 | -23.06 Million USD | -15.89% |
| 2002 FY | -87.82 Million USD | -16.61% |
| 2002 Q4 | -20.94 Million USD | 8.85% |
| 2001 Q2 | -24.87 Million USD | -72.88% |
| 2001 Q3 | -17.29 Million USD | 30.48% |
| 2001 Q4 | -18.74 Million USD | -8.4% |
| 2001 FY | -75.31 Million USD | -75.7% |
| 2001 Q1 | -14.39 Million USD | -20.66% |
| 2000 FY | -42.86 Million USD | -128.0% |
| 2000 Q2 | -12.67 Million USD | -74.11% |
| 2000 Q3 | -10.98 Million USD | 13.28% |
| 2000 Q1 | -7.27 Million USD | 0.0% |
| 2000 Q4 | -11.92 Million USD | -8.55% |
| 1999 FY | -18.8 Million USD | -22.91% |
| 1998 FY | -15.29 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Absci Corporation | -115.51 Million USD | 247.933% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 175.268% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 160.56% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 1819.572% |
| Apollomics, Inc. | -54.83 Million USD | 411.641% |
| 180 Life Sciences Corp. | -13.47 Million USD | 1367.928% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 644.619% |
| Bicycle Therapeutics plc | -189.94 Million USD | 189.965% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 303.643% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 199.478% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 775.969% |
| Chimerix, Inc. | -93.06 Million USD | 283.619% |
| CRISPR Therapeutics AG | -222.53 Million USD | 176.789% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -962.916% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 331.985% |
| Fortress Biotech, Inc. | -142.34 Million USD | 220.052% |
| Fortress Biotech, Inc. | -142.34 Million USD | 220.052% |
| Gritstone bio, Inc. | -154.63 Million USD | 210.509% |
| Allakos Inc. | -196.05 Million USD | 187.161% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 411.857% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 240.652% |
| Cytokinetics, Incorporated | -496.2 Million USD | 134.438% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 755.737% |
| Innoviva, Inc. | 176.7 Million USD | 3.296% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 2321.524% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1547.312% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 234.489% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 1325309.733% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 266.623% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 292.295% |
| ImmuCell Corporation | -5.74 Million USD | 3072.907% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 227.119% |
| Incyte Corporation | 620.52 Million USD | 72.461% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 226.369% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 2715.311% |
| Mustang Bio, Inc. | -50.72 Million USD | 436.879% |
| MiMedx Group, Inc. | 37.11 Million USD | -360.408% |
| MEI Pharma, Inc. | 14.54 Million USD | -1075.113% |
| MacroGenics, Inc. | -168.24 Million USD | 201.57% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 2035.007% |
| Mereo BioPharma Group plc | -28.41 Million USD | 701.369% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 1271.94% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 229.965% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 639.955% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 839.136% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 1175.696% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 1518.25% |
| NextCure, Inc. | -67.63 Million USD | 352.65% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 431.777% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 1717.77% |
| Onconetix, Inc. | -36.03 Million USD | 574.225% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 509.659% |
| Opthea Limited | -191.84 Million USD | 189.076% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 388.26% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 6309.879% |
| PDS Biotechnology Corporation | -43.04 Million USD | 496.989% |
| Precigen, Inc. | -88.92 Million USD | 292.172% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 674.288% |
| Prime Medicine, Inc. | -191.29 Million USD | 189.332% |
| PureTech Health plc | -146.19 Million USD | 216.885% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 165.811% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 95.778% |
| Replimune Group, Inc. | -234.77 Million USD | 172.787% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 2074.028% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 933.951% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 980.011% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 135.076% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 803.039% |
| Sesen Bio, Inc. | -25.9 Million USD | 759.558% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 162.366% |
| Solid Biosciences Inc. | -104.31 Million USD | 263.816% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 174.313% |
| SciSparc Ltd. | -5.77 Million USD | 3060.073% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 291.408% |
| TG Therapeutics, Inc. | 20.63 Million USD | -728.212% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 244.353% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 2448.289% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 145.358% |
| UroGen Pharma Ltd. | -65.53 Million USD | 360.75% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 359.866% |
| XOMA Corporation | -41.84 Million USD | 508.347% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 168.632% |
| AbCellera Biologics Inc. | -237.2 Million USD | 172.04% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 401.071% |
| Cassava Sciences, Inc. | -105.95 Million USD | 261.278% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 479.093% |
| Precision BioSciences, Inc. | -43.73 Million USD | 490.719% |
| Dyadic International, Inc. | -8.22 Million USD | 2176.433% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 2154.153% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 14435.99% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 684.062% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 230.255% |
| IGM Biosciences, Inc. | -263.46 Million USD | 164.862% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 258.93% |
| Acelyrin, Inc. | -422.06 Million USD | 140.488% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 462.544% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -1330.958% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 950.606% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 318.509% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 232.481% |
| Senti Biosciences, Inc. | -92.72 Million USD | 284.288% |
| Mesoblast Limited | -58.79 Million USD | 390.65% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 203.235% |
| ChromaDex Corporation | -5.59 Million USD | 3152.063% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 3666.445% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 469.433% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 2224.932% |
| Seer, Inc. | -103.46 Million USD | 265.165% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 488.287% |
| Novavax, Inc. | -566.51 Million USD | 130.164% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 1189.148% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 189.698% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 427.692% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 169.607% |
| Celcuity Inc. | -66.23 Million USD | 358.016% |
| ContextLogic Inc. | -328 Million USD | 152.099% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 202.136% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 274.919% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 70.465% |
| Amarin Corporation plc | -67.58 Million USD | 352.833% |
| AnaptysBio, Inc. | -164.41 Million USD | 203.938% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 691.748% |
| Aptorum Group Limited | -10.52 Million USD | 1723.868% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 297.747% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 183.358% |
| Ardelyx, Inc. | -63.27 Million USD | 370.063% |
| Celularity Inc. | -192.28 Million USD | 188.87% |
| Omeros Corporation | -164.53 Million USD | 203.863% |
| Humacyte, Inc. | -100.04 Million USD | 270.805% |
| Immunocore Holdings plc | -59.64 Million USD | 386.484% |
| IO Biotech, Inc. | -91.44 Million USD | 286.876% |
| GT Biopharma, Inc. | -13.57 Million USD | 1358.729% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 328.884% |
| Summit Therapeutics Inc. | -89.73 Million USD | 290.431% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 598.687% |
| Pulmatrix, Inc. | -14.74 Million USD | 1259.328% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 133.163% |
| Evogene Ltd. | -26.39 Million USD | 747.512% |
| CorMedix Inc. | -48.95 Million USD | 449.046% |
| BioLineRx Ltd. | -49.69 Million USD | 443.875% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 617.504% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 655.904% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 148.908% |
| scPharmaceuticals Inc. | -55.39 Million USD | 408.479% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 254.418% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -59.286% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1547.312% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 803.039% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 198.852% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 896.073% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 764.715% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 248.89% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 305.754% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 421.658% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 1004.264% |
| Daré Bioscience, Inc. | -30.83 Million USD | 654.104% |
| bluebird bio, Inc. | -244.26 Million USD | 169.96% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 12.115% |
| DBV Technologies S.A. | -76.43 Million USD | 323.578% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 172.532% |
| Galecto, Inc. | -39.9 Million USD | 528.23% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 561.054% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 428.669% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 177.951% |
| GlycoMimetics, Inc. | -39.27 Million USD | 535.095% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 170.877% |
| ADMA Biologics, Inc. | 21.63 Million USD | -689.964% |
| Clene Inc. | -40.54 Million USD | 521.522% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 148.816% |
| Aptose Biosciences Inc. | -52.35 Million USD | 426.39% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 1284.992% |
| Soligenix, Inc. | -7.69 Million USD | 2319.88% |
| Century Therapeutics, Inc. | -146.54 Million USD | 216.608% |
| Kura Oncology, Inc. | -165.8 Million USD | 203.064% |
| Surrozen, Inc. | -45.78 Million USD | 473.274% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 282.847% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 6985.973% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 2735.487% |
| Autolus Therapeutics plc | -195.02 Million USD | 187.621% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 301.856% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 908.54% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 247.24% |
| GRI Bio, Inc. | -11.38 Million USD | 1600.703% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 3884.229% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 334.156% |
| INmune Bio, Inc. | -29.74 Million USD | 674.577% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 254.486% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 548.808% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 1169.411% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 2175.373% |
| Jaguar Health, Inc. | -34.29 Million USD | 598.338% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 1183.551% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 379.69% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 787.832% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 161.914% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 184.097% |
| Verastem, Inc. | -92.08 Million USD | 285.575% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 192.799% |
| Histogen Inc. | -10.64 Million USD | 1705.609% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 1204.482% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 332.88% |
| Surrozen, Inc. | -45.78 Million USD | 473.274% |
| Organovo Holdings, Inc. | -15.08 Million USD | 1232.739% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 3457.114% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 2338.812% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 199.768% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 452.719% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 1222.709% |
| Kronos Bio, Inc. | -121.83 Million USD | 240.265% |
| Turnstone Biologics Corp. | -59.03 Million USD | 389.479% |
| Synaptogenix, Inc. | -8.31 Million USD | 2155.425% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 1271.569% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 5504.333% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 286.371% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 210.204% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 133.045% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 348.159% |
| ESSA Pharma Inc. | -32.13 Million USD | 631.787% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 1097.982% |
| Avid Bioservices, Inc. | -18.67 Million USD | 1014.9% |
| Insmed Incorporated | -709.62 Million USD | 124.081% |
| MediWound Ltd. | -15.29 Million USD | 1217.626% |
| OmniAb, Inc. | -69.41 Million USD | 346.165% |
| Alector, Inc. | -151.74 Million USD | 212.617% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 258.252% |
| Zai Lab Limited | -366.57 Million USD | 146.617% |
| AlloVir, Inc. | -181.33 Million USD | 194.239% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 153.945% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 254.256% |
| Aura Biosciences, Inc. | -84.99 Million USD | 301.062% |
| Immunic, Inc. | -99.22 Million USD | 272.223% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 219.368% |
| Veracyte, Inc. | -85.79 Million USD | 299.178% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 160.637% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 1302.569% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -96.845% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 2580.928% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 1009.32% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 771.375% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -340.403% |
| Fortrea Holdings Inc. | 63.1 Million USD | -170.816% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 221.674% |
| XBiotech Inc. | -37.51 Million USD | 555.572% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 348.159% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 200.555% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 551.253% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 354.596% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 258.365% |
| Agenus Inc. | -159.54 Million USD | 207.105% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 765.647% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 420.658% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 130.022% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 317.71% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 264.774% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 867.914% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 222.911% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 3140.587% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 771.216% |
| Lantern Pharma Inc. | -17.87 Million USD | 1055.863% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 497.407% |
| Ainos, Inc. | -13.2 Million USD | 1393.956% |
| Pluri Inc. | -22.15 Million USD | 871.211% |
| Prothena Corporation plc | -191.03 Million USD | 189.452% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 223.796% |
| Rallybio Corporation | -78.93 Million USD | 316.496% |
| Kodiak Sciences Inc. | -277.32 Million USD | 161.62% |
| Cue Biopharma, Inc. | -52.14 Million USD | 427.686% |
| MeiraGTx Holdings plc | -137.06 Million USD | 224.678% |
| Annexon, Inc. | -143.72 Million USD | 218.899% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 364.34% |
| Moderna, Inc. | -4.23 Billion USD | 104.031% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 1020.766% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 797.974% |
| Blueprint Medicines Corporation | -486.27 Million USD | 135.141% |
| Immix Biopharma, Inc. | -16.14 Million USD | 1158.694% |
| CalciMedica, Inc. | -21.87 Million USD | 881.189% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 219.241% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 199.761% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 351.316% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 152.274% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 578.067% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 352.972% |
| Nutriband Inc. | -4.87 Million USD | 3607.545% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 491.821% |
| Vor Biopharma Inc. | -126.03 Million USD | 235.584% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 95.972% |
| Alkermes plc | 414.12 Million USD | 58.736% |
| ProKidney Corp. | -151.52 Million USD | 212.779% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 364.794% |
| Arcellx, Inc. | -89.88 Million USD | 290.126% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 128.135% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 249.672% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 548.847% |
| Atai Life Sciences N.V. | -125.47 Million USD | 236.195% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 309.317% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 309.909% |
| MediciNova, Inc. | -9.9 Million USD | 1826.065% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 235.223% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 2459.489% |
| GeoVax Labs, Inc. | -26.74 Million USD | 738.991% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 173.713% |
| Biomea Fusion, Inc. | -126.13 Million USD | 235.478% |
| RenovoRx, Inc. | -11.39 Million USD | 1599.517% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 189.427% |
| Geron Corporation | -193.94 Million USD | 188.11% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 719.44% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 251.404% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 170.566% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 778.223% |
| Royalty Pharma plc | 1.49 Billion USD | 88.548% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 182.159% |
| Imunon, Inc. | -21.03 Million USD | 912.561% |
| BioAtla, Inc. | -129.68 Million USD | 231.767% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 152.141% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 509.227% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 199.958% |
| Structure Therapeutics Inc. | -102.77 Million USD | 266.271% |
| 89bio, Inc. | -151.2 Million USD | 213.016% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 262.381% |
| aTyr Pharma, Inc. | -54.91 Million USD | 411.158% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 295.46% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 167.159% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 2180.727% |
| Akari Therapeutics, Plc | -16.8 Million USD | 1116.809% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 1932525.877% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 49.379% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 199.496% |
| Liquidia Corporation | -73.38 Million USD | 332.864% |
| Entera Bio Ltd. | -8.89 Million USD | 2022.0% |
| GH Research PLC | -41.22 Million USD | 514.548% |
| Vericel Corporation | -6.46 Million USD | 2743.642% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 318.794% |
| Xencor, Inc. | -138.63 Million USD | 223.259% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 3415.205% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 1169.411% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 895.142% |
| Vaxcyte, Inc. | -468.04 Million USD | 136.511% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 179.833% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 1324.806% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 2715.311% |
| Portage Biotech Inc. | -18.25 Million USD | 1036.202% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 2459.489% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 262.808% |
| OncoCyte Corporation | -25.13 Million USD | 779.842% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 1611.607% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 1591.526% |
| Purple Biotech Ltd. | 22.27 Million USD | -667.298% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 686.086% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 683.126% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 192.692% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 2374.827% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 676.71% |
| United Therapeutics Corporation | 1.18 Billion USD | 85.578% |
| HilleVax, Inc. | -133.34 Million USD | 228.153% |
| Silo Pharma, Inc. | -3.85 Million USD | 4532.134% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 4434.929% |
| Pharming Group N.V. | -4.87 Million USD | 3602.069% |
| Tharimmune, Inc. | -9.45 Million USD | 1907.309% |
| Genprex, Inc. | -31.07 Million USD | 649.901% |
| Apogee Therapeutics, Inc. | -93 Million USD | 283.741% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 190.803% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 307.899% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 22437.908% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 3237.278% |
| OKYO Pharma Limited | -15.74 Thousand USD | 1085102.727% |
| Savara Inc. | -60 Million USD | 384.775% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 1074.314% |
| Curis, Inc. | -48.33 Million USD | 453.565% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 3375.366% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 727.101% |
| BeiGene, Ltd. | -1.2 Billion USD | 114.149% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 282.468% |
| Erasca, Inc. | -141.52 Million USD | 220.745% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 3874.817% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 3874.817% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 501.054% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 2786.871% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 354.153% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 210.575% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 182.105% |
| Adicet Bio, Inc. | -152.03 Million USD | 212.396% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 332.516% |
| Aditxt, Inc. | -26.06 Million USD | 755.676% |
| Adagene Inc. | -23.71 Million USD | 820.43% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2437.657% |
| Quantum-Si incorporated | -111.17 Million USD | 253.714% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 1272.23% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -40.054% |
| Compugen Ltd. | -12.99 Million USD | 1415.309% |
| Generation Bio Co. | -138.56 Million USD | 223.327% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 305.811% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 297.646% |
| Invivyd, Inc. | -207.78 Million USD | 182.242% |
| Relay Therapeutics, Inc. | -373 Million USD | 145.814% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 1922.092% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -695.517% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 1761.174% |
| 2seventy bio, Inc. | -216.7 Million USD | 178.857% |
| Instil Bio, Inc. | -159.16 Million USD | 207.361% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 809.718% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 4757.445% |
| GeoVax Labs, Inc. | -26.74 Million USD | 738.991% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 565.221% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 264.785% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 200.356% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 124.972% |
| Evaxion Biotech A/S | -22.19 Million USD | 869.856% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 307.43% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 176.587% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 313.753% |
| Cingulate Inc. | -22.75 Million USD | 850.84% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -2180.9% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 482.576% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 375.292% |
| Clearmind Medicine Inc. | -8.74 Million USD | 2054.904% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 324.27% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 5926.317% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 269.483% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 144.911% |
| ImmunityBio, Inc. | -362.25 Million USD | 147.173% |
| Korro Bio, Inc. | -84.53 Million USD | 302.149% |
| Kineta, Inc. | -15.72 Million USD | 1186.847% |
| BioVie Inc. | -32.17 Million USD | 631.035% |
| Codexis, Inc. | -68.06 Million USD | 351.047% |
| Celularity Inc. | -192.28 Million USD | 188.87% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 1149.92% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 176.765% |
| Virax Biolabs Group Limited | -6.49 Million USD | 2730.427% |
| Cibus, Inc. | -318.88 Million USD | 153.589% |
| IN8bio, Inc. | -30.33 Million USD | 663.289% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 238.043% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 828.907% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 148.309% |
| Eyenovia, Inc. | -25.4 Million USD | 772.605% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -423.545% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 3172.366% |
| Elevation Oncology, Inc. | -45.44 Million USD | 476.026% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 315.947% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 476.299% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 224.545% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 649.31% |
| Moolec Science SA | -6.65 Million USD | 2668.23% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 379.507% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 495.082% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 204.095% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 439.307% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 1931.984% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 880.487% |
| Humacyte, Inc. | -100.04 Million USD | 270.805% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 313.254% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 1275.275% |
| Genelux Corporation | -24.16 Million USD | 807.159% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 603.744% |
| Notable Labs, Ltd. | -14.65 Million USD | 1265.893% |
| Immunovant, Inc. | -282.7 Million USD | 160.446% |
| Quantum-Si incorporated | -111.17 Million USD | 253.714% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 903.522% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 267.515% |
| Acasti Pharma Inc. | -11.31 Million USD | 1610.652% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 845.536% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 512.925% |
| PepGen Inc. | -84.76 Million USD | 301.596% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 846.32% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 620.862% |
| Immuneering Corporation | -58.41 Million USD | 392.547% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 3457.114% |
| Belite Bio, Inc | -31.66 Million USD | 639.614% |
| XOMA Corporation | -41.84 Million USD | 508.347% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 353.088% |
| Bionomics Limited | -17.89 Billion USD | 100.955% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -378.938% |
| uniQure N.V. | -282.87 Million USD | 160.411% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2437.657% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 231.953% |
| Forte Biosciences, Inc. | -32.48 Million USD | 626.027% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 2156.686% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 681.34% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 3172.366% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 1302.569% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 2022.432% |
| Altimmune, Inc. | -95.92 Million USD | 278.137% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 333.737% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -378.938% |
| Peak Bio, Inc. | -1356.23 USD | 12600101.475% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 444.498% |
| Benitec Biopharma Inc. | -22.49 Million USD | 859.827% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 170.525% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 674.481% |
| Zura Bio Limited | -62.63 Million USD | 372.814% |
| PolyPid Ltd. | -22.86 Million USD | 847.3% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 674.481% |
| argenx SE | -425.04 Million USD | 140.204% |
| Immunome, Inc. | -109.53 Million USD | 256.017% |
| Verona Pharma plc | -67.83 Million USD | 351.928% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 755.737% |
| Shattuck Labs, Inc. | -91.95 Million USD | 285.831% |
| CervoMed Inc. | -7.81 Million USD | 2287.217% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 1382.824% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 454.725% |
| Moolec Science SA | -6.65 Million USD | 2668.23% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 1138.913% |
| Design Therapeutics, Inc. | -78.19 Million USD | 318.551% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 296.327% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 521.949% |
| Achilles Therapeutics plc | -75.25 Million USD | 327.075% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 5926.317% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 408.184% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 436.15% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 358.529% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 415.734% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 476.324% |
| Beam Therapeutics Inc. | -176.48 Million USD | 196.827% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 256.554% |
| AEON Biopharma, Inc. | -48.42 Million USD | 452.857% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 337.561% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 304.582% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 1457.642% |
| NeurAxis, Inc. | -6.66 Million USD | 2664.11% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 137.104% |
| Lumos Pharma, Inc. | -36.61 Million USD | 566.72% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -3214.094% |
| Palisade Bio, Inc. | -13.07 Million USD | 1407.46% |
| Nutriband Inc. | -4.87 Million USD | 3607.545% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 335.902% |
| Neurogene Inc. | -55.58 Million USD | 407.441% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 2110.175% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 276.698% |
| Athira Pharma, Inc. | -125.46 Million USD | 236.2% |
| HCW Biologics Inc. | -25.71 Million USD | 764.479% |
| XOMA Corporation | -41.84 Million USD | 508.347% |
| Nektar Therapeutics | -137.42 Million USD | 224.348% |
| Arvinas, Inc. | -401.5 Million USD | 142.562% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 1932525.877% |
| Merus N.V. | -156.54 Million USD | 209.159% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 270.44% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 593.602% |
| Rezolute, Inc. | -70.42 Million USD | 342.655% |
| Clene Inc. | -40.54 Million USD | 521.522% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 1143.351% |
| BeyondSpring Inc. | -23.11 Million USD | 839.314% |
| Synlogic, Inc. | -55.16 Million USD | 409.793% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 1053.121% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 1678.76% |
| Peak Bio, Inc. | -1356.23 USD | 12600101.475% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 521.907% |
| Krystal Biotech, Inc. | -109.72 Million USD | 255.737% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 231.917% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 149.819% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 3700.647% |
| MannKind Corporation | 8.67 Million USD | -1869.175% |
| Ikena Oncology, Inc. | -75.41 Million USD | 326.587% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 1871.38% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 354.18% |
| Gossamer Bio, Inc. | -183.75 Million USD | 192.994% |
| CohBar, Inc. | -12.38 Million USD | 1479.407% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 436.892% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 719.44% |
| Legend Biotech Corporation | -439.48 Million USD | 138.883% |
| Mural Oncology plc | -194.63 Million USD | 187.796% |
| Disc Medicine, Inc. | -91.12 Million USD | 287.528% |
| Champions Oncology, Inc. | -7.35 Million USD | 2423.07% |
| REGENXBIO Inc. | -268.12 Million USD | 163.733% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 1694.346% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 406.487% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 538.609% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 249.431% |
| Vaxart, Inc. | -83.34 Million USD | 305.028% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 2105.691% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 499.319% |
| Cellectis S.A. | -106.62 Million USD | 260.266% |
| Longeveron Inc. | -21.02 Million USD | 912.616% |
| Repare Therapeutics Inc. | -116.22 Million USD | 247.031% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 163.805% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 325.904% |
| Revolution Medicines, Inc. | -487.18 Million USD | 135.076% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 2668.927% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 488.781% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 329.099% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 345.401% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 1651.948% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 96.033% |
| Denali Therapeutics Inc. | -196.69 Million USD | 186.876% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 2074.028% |
| Veru Inc. | -93.78 Million USD | 282.215% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 832.5% |
| Cingulate Inc. | -22.75 Million USD | 850.84% |
| Passage Bio, Inc. | -108.38 Million USD | 257.659% |
| Context Therapeutics Inc. | -25.07 Million USD | 781.56% |
| Exicure, Inc. | -14.99 Million USD | 1239.537% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 182.928% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 520.92% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 1858.63% |
| Nuvalent, Inc. | -149.49 Million USD | 214.31% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 2179.776% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 292.588% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 922.591% |
| OmniAb, Inc. | -69.41 Million USD | 346.165% |
| Anew Medical, Inc. | -1.3 Million USD | 13236.512% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 1438.071% |
| Lipocine Inc. | -17.93 Million USD | 1053.017% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 349.42% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 324.4% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 548.808% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 532.325% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 863.425% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 129.471% |
| Ocugen, Inc. | -65.53 Million USD | 360.77% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 282.052% |
| Q32 Bio Inc. | -92.1 Million USD | 285.539% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 897.075% |
| Alumis Inc. Common Stock | -158.17 Million USD | 208.036% |
| Equillium, Inc. | -14.52 Million USD | 1276.732% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 373.828% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 2262.185% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1005.826% |
| Dominari Holdings Inc. | -21.79 Million USD | 884.02% |
| Edesa Biotech, Inc. | -9.22 Million USD | 1952.862% |
| vTv Therapeutics Inc. | -25.5 Million USD | 770.085% |
| Bio-Techne Corporation | 206.68 Million USD | 17.321% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 143.65% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 11.011% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 229.187% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 545.117% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 213.093% |
| Nkarta, Inc. | -131.65 Million USD | 229.803% |
| BioCardia, Inc. | -11.64 Million USD | 1567.58% |
| Iterum Therapeutics plc | -47.46 Million USD | 460.0% |